 |
|
European Study on Intravenous Immunoglobulin in Multiple Sclerosis
Results of Magnetization Transfer Magnetic Resonance Imaging Analysis
Massimo Filippi, MD;
Maria A. Rocca, MD;
Elisabetta Pagani, PhD;
Giuseppe Iannucci, MD;
Maria Pia Sormani, PhD;
Franz Fazekas, MD;
Stefan Ropele, PhD;
Otto R. Hommes, MD;
Giancarlo Comi, MD
Arch Neurol. 2004;61:1409-1412.
Background Magnetization transfer magnetic resonance imaging (MT MRI) can provide in vivo markers reflecting the severity of multiple sclerosis–related brain damage occurring within and outside T2-visible lesions.
Objective To investigate the effect of intravenous immunoglobulin (IVIG) treatment on the accumulation of brain damage in patients with secondary progressive multiple sclerosis (SPMS), measured using MT MRI.
Design, Patients, and Intervention Seventy patients with SPMS participating in the European, multicenter, randomized, double-blind, placebo-controlled trial of IVIG in SPMS underwent brain T2-weighted and MT MRI at baseline and after 12 and 24 months. The MT MRI scans were post-processed and analyzed to obtain MT ratio values from T2-visible lesions and MT ratio histograms from the normal-appearing brain tissue (NABT).
Results At baseline, a significant difference was found for NABT MT ratio histogram peak height (P = .003) between treated patients and patients receiving placebo. No significant differences between treated patients and those receiving placebo were found for any of the considered MT MRI–derived metrics in terms of treatment x time interaction. Nevertheless, over the 24-month period, the placebo patients experienced a 6.75% reduction of the NABT MT ratio histogram peak height, whereas treated patients experienced only a 0.92% reduction of the NABT MT ratio histogram peak height.
Conclusions This study did not show any statistically significant effect of IVIG on MT MRI quantities. Nevertheless, the markedly different percentage change of the NABT MT ratio histogram peak height over time between patients receiving placebo and treated patients suggests a possible role of IVIG treatment in preventing the loss of "truly" normal brain tissue in SPMS patients.
Author Affiliations: Neuroimaging Research Unit (Drs Filippi, Rocca, Pagani, Iannucci, and Sormani), and the Department of Neurology, Scientific Institute and University Ospedale San Raffaele, Milan, Italy (Drs Filippi, Rocca, Pagani, and Comi); Department of Neurology, Karl Franzens University, Graz, Austria (Drs Fazekas and Ropele); and the Multiple Sclerosis Centre, Nijmegen, the Netherlands (Dr Hommes).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer et al.
Brain 2009;132:1175-1189.
ABSTRACT
| FULL TEXT
Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins
Stangel
Therapeutic Advances in Neurological Disorders 2008;1:115-124.
ABSTRACT
Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives
Bar-Zohar et al.
Mult Scler 2008;14:719-727.
ABSTRACT
Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis
Rovaris et al.
Mult Scler 2008;14:455-464.
ABSTRACT
Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis
Agosta et al.
Brain 2006;129:2620-2627.
ABSTRACT
| FULL TEXT
MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS)
Fazekas et al.
Mult Scler 2005;11:433-440.
ABSTRACT
|
